The global stomach cancer treatment market is anticipated to witness impressive growth through 2028, according to a study by Research & Markets. This can be ascribed to the growing development of novel drugs and therapies for treating stomach cancer.
Additionally, growing demand for painless low-cost treatment and favorable reimbursement scenarios for the treatment of cancer have significantly increased the growth of stomach cancer treatment across different parts of the globe.
Additionally, the growing aging population across the globe, which is more prone to different kinds of chronic diseases like stomach cancer, is further expected to increase the demand for different cancer therapies, thereby fuelling market growth through 2028.
Besides, growing awareness about the benefits of new therapies, with increasing expenditure on cancer diseases worldwide, is further expected to support the stomach cancer treatment market during the forecast period.
Increasing incidences of adenocarcinoma, lymphoma, and gastrointestinal stromal tumors across the world are driving market growth during the forecast period. Similarly, the rising aging population is susceptible to chronic diseases like stomach cancer, which is one of the most common deadly cancers worldwide, especially among older males. This is expected to boost market growth in the forecast period.
According to the National Cancer Institute, in 2022, 26,380 new stomach cancer cases and 11,090 deaths are estimated in the United States. In developing countries, stomach cancer is more diagnosed in males than females because females carry an extra copy of certain protective genes in their cells that men don't have.
The increasing prevalence of gastric cancer in the region is demanding effective therapies for treating patients, which, in turn, is expected to propel the market growth during the forecast period. For instance, according to the 2021 statistics published by the Canadian Cancer Society, 4,000 Canadians were affected by gastric cancer.